Paricalcitol: An updated review and guidelines for use

Dialysis and Transplantation

Volumn 30, Issue 10, 2001, Pages 654-664

  Llach, F ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM ION; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO;

ADULT; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; STATISTICAL ANALYSIS;

EID: 0034787544     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. The evolving pattern of calcific uremic arteriolopathy
2. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
3. Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriol
4. Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited
5. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
6. Management of secondary hyperparathyroidism: The gap between diagnosis and treatment
7. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure
8. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
9. 2 on calcium and phosphorus resorption in bone
10. 2 (19-nor) on bone resorption in hemodialysis (HD) patients
11. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
12. 2 (19-Nor), An analog of calcitriol, suppresses parathyroid gland growth in uremic rats with established secondary hyperparathyroidism
13. Clpl/WAF1 and reducing transforming growth factor-alpha (TGFalpha) expression
14. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro
15. The effect of paricalcitol and calcitriol on bone formation
16. 2
17. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
18. 2
19. Long-term (1.5 year) paricalcitol therapy for protracted hyperparathyroidism in patients on dialysis
20. Long-term therapeutic effects of paricalcitol in hemodialysis patients
21. 2 and intravenous calcitriol on PTH suppression in hemodialysis patients
22. Paricalcitol as initial therapy for hyperparathyroidism in patients starting maintenance hemodialysis
23. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis
24. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients